2 482

Cited 33 times in

Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma

DC Field Value Language
dc.contributor.author김창훈-
dc.contributor.author윤주헌-
dc.date.accessioned2014-12-21T16:25:55Z-
dc.date.available2014-12-21T16:25:55Z-
dc.date.issued2007-
dc.identifier.issn0385-8146-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/95681-
dc.description.abstractOBJECTIVE: Olfactory neuroblastomas are very aggressive tumors with a high locoregional recurrence rate and distant metastasis. Surgical treatment, including craniofacial resection, has been the main treatment modality, but treatment outcomes of concurrent chemoradiotherapy remain unclear. We present our experiences regarding the treatment outcome of patients with advanced olfactory neuroblastoma undergoing surgical treatment and concurrent chemoradiotherapy. METHODS: We retrospectively analyzed 16 patients treated for advanced olfactory neuroblastoma within the past 10 years. RESULTS: The disease-free 5-year survival rate of the patients (n = 10) who underwent surgical treatment was 68%. The survival rate for patients (n = 6) who received concurrent chemoradiotherapy was 42%. The difference in the survival rate was not statistically significant, and no difference in the recurrence rate between the two groups. In the group having surgical treatment, post-operative radiotherapy and salvage therapy were important to increase the survival rate. In the group having concurrent chemoradiotherapy, no patient experienced primary tumor progression. CONCLUSION: Complete surgical resection, including craniofacial resection (CFR), and post-operative radiotherapy seem to be essential in the treatment of advanced olfactory neuroblastoma. However, concurrent chemoradiotherapy may be another primary treatment modality.-
dc.description.statementOfResponsibilityopen-
dc.format.extent493~498-
dc.relation.isPartOfAURIS NASUS LARYNX-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleSurgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Otorhinolaryngology (이비인후과학)-
dc.contributor.googleauthorHyun Jik Kim-
dc.contributor.googleauthorChang-Hoon Kim-
dc.contributor.googleauthorJoo-Heon Yoon-
dc.contributor.googleauthorYoon-Seok Choi-
dc.contributor.googleauthorJin Kook Kim-
dc.contributor.googleauthorYoo-Sam Chung-
dc.contributor.googleauthorBong-Jae Lee-
dc.identifier.doi10.1016/j.anl.2007.02.005-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01050-
dc.contributor.localIdA02604-
dc.relation.journalcodeJ00263-
dc.identifier.eissn1879-1476-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0385814607000557-
dc.contributor.alternativeNameKim, Chang Hoon-
dc.contributor.alternativeNameYoon, Joo Heon-
dc.contributor.affiliatedAuthorKim, Chang Hoon-
dc.contributor.affiliatedAuthorYoon, Joo Heon-
dc.rights.accessRightsnot free-
dc.citation.volume34-
dc.citation.number4-
dc.citation.startPage493-
dc.citation.endPage498-
dc.identifier.bibliographicCitationAURIS NASUS LARYNX, Vol.34(4) : 493-498, 2007-
dc.identifier.rimsid45016-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.